Clinical trial
Assessment of the Role of Tegaserod Therapy in the Management of…
NCT00171483 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171483 |
|---|---|
| Title | Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). |
| Official title | Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux Disease (GERD) |
| Intervention type | Drug |
| Interventions | Tegaserod |
| Enrollment | 30 |
| Start date | Jan 1, 2004 |
| Completion | Apr 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 28, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: